Education
About Us
Working with TipRanks
Follow Us
Qualigen Therapeutics Inc (QLGN)
NASDAQ:QLGN
RESEARCH TOOLSreports
QLGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.85 - $29.41
Previous CloseN/A
Volume8.82K
Average Volume (3M)9.92K
Market Cap
$2.65M
Enterprise Value$3.73M
Total Cash (Recent Filing)$388.15K
Total Debt (Recent Filing)$1.43M
Price to Earnings (P/E)―
Beta1.40
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-55.30
Shares Outstanding736,431
10 Day Avg. Volume7,155
30 Day Avg. Volume9,923
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.28
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue0.13
Enterprise Value/Gross Profit-3.32
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Qualigen Therapeutics News
PremiumCompany Announcements
Qualigen Therapeutics Faces Nasdaq Delisting Notification
PremiumCompany Announcements
Qualigen Therapeutics Faces Nasdaq Delisting Threat
PremiumCompany Announcements
Qualigen Therapeutics Delays Yearly Financial Report
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.27% Mutual Funds
1.05% Other Institutional Investors
98.62% Public Companies and Individual Investors
QLGN FAQ
What was Qualigen Therapeutics Inc’s price range in the past 12 months?
Qualigen Therapeutics Inc lowest stock price was $2.85 and its highest was $29.41 in the past 12 months.
What is Qualigen Therapeutics Inc’s market cap?
Qualigen Therapeutics Inc’s market cap is $2.65M.
When is Qualigen Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Qualigen Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Qualigen Therapeutics Inc overvalued?
According to Wall Street analysts Qualigen Therapeutics Inc’s price is currently Overvalued.
Does Qualigen Therapeutics Inc pay dividends?
Qualigen Therapeutics Inc does not currently pay dividends.
What is Qualigen Therapeutics Inc’s EPS estimate?
Qualigen Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qualigen Therapeutics Inc have?
Qualigen Therapeutics Inc has 736,431 shares outstanding.
What happened to Qualigen Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Qualigen Therapeutics Inc?
Currently, no hedge funds are holding shares in QLGN
Company Description
Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc. (QLGN) is a biotechnology company that focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. The company operates in the healthcare sector, emphasizing innovative drug candidates and diagnostic technologies. Qualigen's core offerings include a pipeline of proprietary drug candidates aimed at addressing unmet medical needs in oncology and infectious diseases.
Technical Analysis
Cyclacel Pharmaceuticals
―
Avadel Pharmaceuticals
―
SELLAS Life Sciences Group
―
Karyopharm Therapeutics
―